Form 4 for TMDX TransMedics Group, Inc.
Accepted 2021-12-28 00:00:00 ET · period of report 2021-12-23 · accession 0000899243-21-049930 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2021-12-28 | 2021-12-23 | TMDX | Provost Miriam | VP of US Regulatory, FDA Rel | M - OptEx | $3.22 | +884 | 9,438 | +10% | +$2,846 |
| D | 2021-12-28 | 2021-12-23 | TMDX | Provost Miriam | VP of US Regulatory, FDA Rel | M - OptEx | $0.00 | -884 | 20.9K | -4% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2021-12-23 | M | A | 884 | $3.22 | 9,438 | D | — | — | |
| 2 | Derivative | Stock Option (Right to Buy) | 2021-12-23 | M | D | 884 | $0.00 | 20,881 | D | $3.22 · — to 2028-04-05 | 884 Common Stock | (F1) The option vested 25% on the first anniversary of the vesting commencement date, February 20, 2018, and at a rate of 2.0833% each month thereafter until the option is fully vested on the fourth anniversary of the vesting date. |